CF PHARMTECH (02652.HK) plans to issue in total 21.75 million shares by placement, with estimated net proceeds of HKD 294.81 million
NewTimeSpace (newtimespace.com) News, CF PHARMTECH (02652.HK) announced on Jul 31, 2026 that the company has entered into a placement agreement with the placement agent on Jul 31, 2026. According to the agreement, the placing agent conditionally agreed to use its best endeavors to procure placees to subscribe for in total 21.75 million shares placement, which represent approximately 5.28% of the company's existing issued share capital as of the date of this announcement, and approximately 5.01% after the subscription.
The placement price per share is HKD 13.82. The total proceeds from the placement are estimated to be about HKD 300.55 million. After deducting the placement commission, professional fees, and all related expenses that the company may incur, the net proceeds from the placement are estimated to be approximately HKD 294.81 million.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CF PHARMTECH (02652.HK): ICF004 Phase I First Subject Dosed for ILD
- CF PHARMTECH (02652.HK): ICF001 expands indications after implied approval from NMPA, covering four indications including pulmonary fibrosis
- CF PHARMTECH(02652.HK) closed 7.26% higher
- NewTimeSpace | CF PharmTech (02652.HK) Shares Rebound on R&D Breakthrough; High Valuation Overshadowed by 90%+ Reliance on Single Product
- YZYBIO-B (02496.HK): Proposes Issuing 35.59 Million Domestic Shares to Three Directors at RMB 2.43 Each, Raising about RMB 83 Million; Whitewash Waiver Sought and Trading to Resume